What are Partial mu-opioid receptor agonist drugs?

Partial mu-opioid receptor agonist drugs are pharmacologic agents that share a common mechanism (typically targeting Mu-opioid receptor (μ-OR)). 12 are currently marketed, with 13 more in clinical development.

What are the marketed Partial mu-opioid receptor agonist drugs?

Marketed Partial mu-opioid receptor agonist drugs include Sublingual Buprenorphine (SLB), Subutex, Buprenorphine Hydrochloride, SCH 28444, Buprenorphine SL, Immediate Release Sublingual Buprenorphine, TM buprenorphine, Injectable buprenorphine.

Partial mu-opioid receptor agonist

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

12 marketed 13 in Phase 3

This page covers all Partial mu-opioid receptor agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Mu-opioid receptor (μ-OR), Mu-opioid receptor (OPRM1), Mu-opioid receptor.

Targets

Mu-opioid receptor (μ-OR) · Mu-opioid receptor (OPRM1) · Mu-opioid receptor

Marketed (12)

Sublingual Buprenorphine (SLB) · NYU Langone Health · Addiction Medicine / Pain Management
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the brain, reducing cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.
Subutex, Buprenorphine Hydrochloride, SCH 28444 · Indivior Inc. · Psychiatry / Addiction Medicine
Buprenorphine is a partial mu-opioid receptor agonist that reduces cravings and withdrawal symptoms in opioid use disorder.
Buprenorphine SL · New York State Psychiatric Institute · Psychiatry / Addiction Medicine
Buprenorphine is a partial mu-opioid receptor agonist that reduces cravings and withdrawal symptoms in opioid use disorder.
Immediate Release Sublingual Buprenorphine · Royal Victoria Hospital, Canada · Addiction Medicine / Pain Management
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.
TM buprenorphine · Indivior Inc. · Psychiatry / Addiction Medicine
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.
Injectable buprenorphine · University of California, San Francisco · Psychiatry / Addiction Medicine
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.
Injectable subcutaneous buprenorphine · VA Office of Research and Development · Pain Management; Substance Use Disorder
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce pain and suppress opioid withdrawal symptoms.
Subutex (SCH 028444) · Merck Sharp & Dohme LLC · Psychiatry / Addiction Medicine
Subutex (buprenorphine) is a partial mu-opioid receptor agonist that reduces opioid cravings and withdrawal symptoms while carrying lower overdose risk than full opioids.
Transmucosal Buprenorphine · Indivior Inc. · Pain Management, Addiction Medicine
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.
Buprenorphine Buccal Film [Belbuca] · Carolinas Pain Institute · Pain Management
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce pain perception.
Buprenorphine (Experimental) · University of Alabama at Birmingham · Pain Management; Substance Use Disorder
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system, producing analgesia and reducing opioid cravings.
Use of buprenorphine with FAO > 30 OME · Fox Chase Cancer Center · Pain Management / Opioid Use Disorder
Buprenorphine is a partial mu-opioid receptor agonist that provides analgesia and is used in opioid-dependent patients, with dose adjustment required when combined with other opioids exceeding 30 oral morphine equivalents.

Phase 3 pipeline (13)

BNX sublingual tablets · Orexo AB · Pain Management / Addiction Medicine
BNX is a buprenorphine sublingual tablet that binds to opioid receptors to provide analgesia and opioid dependence treatment.
BNX sublingual film · Orexo AB · Pain Management / Addiction Medicine
BNX is a buprenorphine sublingual film that binds to opioid receptors to provide analgesia and opioid dependence treatment.
Buprenorphine +OTP · Friends Research Institute, Inc. · Psychiatry / Addiction Medicine
Buprenorphine is a partial mu-opioid receptor agonist combined with opioid treatment program (OTP) services to reduce opioid use disorder symptoms and cravings.
Buprenorphine Injectable Product · King's College London · Pain Management; Opioid Use Disorder
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce pain and opioid cravings while carrying lower overdose risk than full agonists.
Buprenorphine transdermal delivery system · Purdue Pharma LP · Pain Management; Opioid Use Disorder
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to produce analgesia and reduce opioid cravings.
High Dose Buprenorphine · Rutgers, The State University of New Jersey · Pain Management, Addiction Medicine
High-dose buprenorphine is a partial mu-opioid receptor agonist that provides stronger analgesia and opioid dependence treatment at elevated doses compared to standard formulations.
oPLB · National Institute on Drug Abuse (NIDA) · Psychiatry / Addiction Medicine
oPLB is a long-acting buprenorphine formulation designed to provide sustained opioid agonist therapy for opioid use disorder.
Buprenorphine transdermal patches · Mundipharma (China) Pharmaceutical Co. Ltd · Pain Management / Addiction Medicine
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce opioid cravings.
Buprenorphine Transdermal Matrix Patch · Washington University School of Medicine · Pain Management; Opioid Use Disorder
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce opioid cravings.
DFN-15 Active · BioDelivery Sciences International · Pain Management
DFN-15 is a buprenorphine sublingual tablet formulation designed to provide rapid onset and consistent opioid receptor agonism for pain management.
Low Bup Dose · New York State Psychiatric Institute · Pain Management / Psychiatry / Substance Use Disorder
Low-dose buprenorphine acts as a partial agonist at the mu-opioid receptor, providing analgesia and potentially reducing opioid cravings with lower overdose risk than full opioids.
High Bup Dose · New York State Psychiatric Institute · Psychiatry / Addiction Medicine
High-dose buprenorphine is a partial mu-opioid receptor agonist that provides analgesia and opioid dependence treatment through sustained receptor occupancy.
EN3409 · BioDelivery Sciences International · Pain Management / Opioid Use Disorder
EN3409 is a buprenorphine formulation designed to provide sustained opioid receptor agonism with reduced abuse potential through a specialized delivery technology.

Patent intelligence

partial mu opioid receptor agonist patent landscape — aggregated cliff calendar, attackable patents, originator estates